David Glusko
Family Medicine · Meyersdale, PANPI 1295737518
Payments from drug & device makers
Across 408 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$893
- AbbVie$870
- AstraZeneca$492
- GSK$474
- Astellas Pharma US Inc$437
- Lilly USA, LLC$424
- plus $3K from 34 others
What the payments were for
- Food & beverage$6,37496%
- Education$2323%
- Other$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,656 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 198 | $225,645 |
| EliquisApixaban | 225 | $182,295 |
| JardianceEmpagliflozin | 130 | $97,764 |
| MounjaroTirzepatide | 86 | $92,813 |
| OzempicSemaglutide | 69 | $75,821 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $50,390 |
| XareltoRivaroxaban | 50 | $35,073 |
| JanuviaSitagliptin Phosphate | 47 | $32,565 |
| TradjentaLinagliptin | 47 | $29,316 |
| RybelsusSemaglutide | 22 | $26,870 |
| MyrbetriqMirabegron | 39 | $25,580 |
| Breo ElliptaFluticasone/Vilanterol | 57 | $25,301 |
| LinzessLinaclotide | 30 | $21,231 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $21,021 |
| EntrestoSacubitril/Valsartan | 13 | $17,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $424 | $318,458284 claims |
| PfizerEliquis | $414 | $182,295225 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat, Synjardy | $187 | $154,695224 claims |
| Novo NordiskOzempic, Rybelsus | $893 | $102,69191 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $474 | $83,755149 claims |
| Johnson & JohnsonXarelto | $94 | $35,07350 claims |
| MerckJanuvia | $168 | $32,56547 claims |
| Astellas Pharma US IncMyrbetriq | $437 | $25,58039 claims |
| AbbVieLinzess, Synthroid | $870 | $24,70499 claims |
| AstraZenecaFarxiga, Brilinta | $492 | $18,56728 claims |
| NovartisEntresto | $56 | $17,47013 claims |
| Sanofi-aventis U.S. LLCMultaq | $40 | $15,91121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Meyersdale
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.